Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer
Copyright © 2018 Elsevier GmbH. All rights reserved..
BACKGROUND: An increasing number of breast cancer patients in Asian countries has been found to consume dietary supplements including phytoestrogen-rich Chinese herbal medicines with an expectation to alleviate the side effects of conventional cancer therapies.
PURPOSE: The question of whether estrogenic Chinese herbal medicines are beneficial or detrimental to the health of breast cancer patients remains uncertain.
STUDY DESIGN: The present study aimed at establishing a systematic approach to look at the safety profiles of estrogenic Chinese herbal medicines (CHM).
METHODS: The effects of estrogenic CHM on the growth of human breast cancer cells as well as the progression of breast tumors in mice have been investigated.
RESULTS: Our results demonstrated that among 10 selected estrogenic CHM, the aqueous extracts of Cistanche deserticola (CD) and Dioscorea opposita (DO) at 0.4 to 1.6 mg/ml significantly stimulated cell viability in both estrogen receptor (ER)-positive (MDA-MB-361 and MCF-7) and ER-negative (SKBR3 and MDA-MB-231) breast cancer cells. However, results from animal studies showed that no significant difference was found on the size of mouse 4T1 breast tumors in CD- and DO-treated mice when compared with the control group, while the number of proliferative cells were found to be increased in DO-treated group. Besides, CD and DO treatments induced significant immunomodulatory effects on 4T1 tumor-bearing mice by increasing the production of cytokines IL-2 and IFN-γ and modulation of regulatory T-cells. Furthermore, CD and DO treatments did not stimulate, but in fact suppressed human triple-negative MDA-MB-231 breast xenografts growth in immunodeficiency mice.
CONCLUSION: The considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Phytomedicine : international journal of phytotherapy and phytopharmacology - 56(2019) vom: 15. März, Seite 103-117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yue, Grace Gar-Lee [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Phytogenic |
|---|
| Anmerkungen: |
Date Completed 20.05.2019 Date Revised 20.05.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phymed.2018.10.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292959451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292959451 | ||
| 003 | DE-627 | ||
| 005 | 20231225074252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phymed.2018.10.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0976.xml |
| 035 | |a (DE-627)NLM292959451 | ||
| 035 | |a (NLM)30668331 | ||
| 035 | |a (PII)S0944-7113(18)30524-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yue, Grace Gar-Lee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2019 | ||
| 500 | |a Date Revised 20.05.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier GmbH. All rights reserved. | ||
| 520 | |a BACKGROUND: An increasing number of breast cancer patients in Asian countries has been found to consume dietary supplements including phytoestrogen-rich Chinese herbal medicines with an expectation to alleviate the side effects of conventional cancer therapies | ||
| 520 | |a PURPOSE: The question of whether estrogenic Chinese herbal medicines are beneficial or detrimental to the health of breast cancer patients remains uncertain | ||
| 520 | |a STUDY DESIGN: The present study aimed at establishing a systematic approach to look at the safety profiles of estrogenic Chinese herbal medicines (CHM) | ||
| 520 | |a METHODS: The effects of estrogenic CHM on the growth of human breast cancer cells as well as the progression of breast tumors in mice have been investigated | ||
| 520 | |a RESULTS: Our results demonstrated that among 10 selected estrogenic CHM, the aqueous extracts of Cistanche deserticola (CD) and Dioscorea opposita (DO) at 0.4 to 1.6 mg/ml significantly stimulated cell viability in both estrogen receptor (ER)-positive (MDA-MB-361 and MCF-7) and ER-negative (SKBR3 and MDA-MB-231) breast cancer cells. However, results from animal studies showed that no significant difference was found on the size of mouse 4T1 breast tumors in CD- and DO-treated mice when compared with the control group, while the number of proliferative cells were found to be increased in DO-treated group. Besides, CD and DO treatments induced significant immunomodulatory effects on 4T1 tumor-bearing mice by increasing the production of cytokines IL-2 and IFN-γ and modulation of regulatory T-cells. Furthermore, CD and DO treatments did not stimulate, but in fact suppressed human triple-negative MDA-MB-231 breast xenografts growth in immunodeficiency mice | ||
| 520 | |a CONCLUSION: The considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cistanche deserticola | |
| 650 | 4 | |a Dioscorea opposita | |
| 650 | 4 | |a Estrogen receptor | |
| 650 | 4 | |a Estrogenic herbs | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a Antineoplastic Agents, Phytogenic |2 NLM | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 650 | 7 | |a Phytoestrogens |2 NLM | |
| 700 | 1 | |a Wong, Lok-Sze |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Hoi-Wing |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Si |e verfasserin |4 aut | |
| 700 | 1 | |a Tsang, Julia Yuen-Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhi-Xiu |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Gary Man-Kit |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Clara Bik-San |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytomedicine : international journal of phytotherapy and phytopharmacology |d 1994 |g 56(2019) vom: 15. März, Seite 103-117 |w (DE-627)NLM093820402 |x 1618-095X |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2019 |g day:15 |g month:03 |g pages:103-117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phymed.2018.10.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2019 |b 15 |c 03 |h 103-117 | ||